title: Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
abstract: Retinoids reverse the abnormal pattern of keratinization seen in acne vulgaris. Tazarotene is the first of a novel family of topical receptor-selective acetylenic retinoids. This study evaluates the safety and efficacy of topical tazarotene 0.1% and 0.05% gels, in comparison to vehicle gel, applied once daily for 12 weeks, in the treatment of mild-to-moderate facial acne vulgaris. A total of 446 patients with facial acne vulgaris were enrolled, and 375 patients, ranging in age from 14 to 44 years, were evaluable in this multicenter, double-blind, randomized study. In comparison to vehicle gel, treatment with tazarotene 0.1% gel resulted in significantly greater reductions in noninflammatory and total lesion counts at all follow-up visits, and inflammatory lesion counts at Week 12. Tazarotene 0.05% gel resulted in significantly greater reductions in noninflammatory and total lesion counts than vehicle gel at Weeks 8 and 12. At Week 12, treatment success rates were 68% and 51% for tazarotene 0.1% and 0.05%, respectively (40% for vehicle gel). Tazarotene gel was an effective, safe, and generally well-tolerated therapy for the treatment of acne vulgaris.
authors.affiliation: Department of Dermatology, Downstate Medical Center, Brooklyn, State University of New York 11203, USA.
authors.forename: A R
authors.initials: AR
authors.lastname: Shalita
authors.forename: D K
authors.initials: DK
authors.lastname: Chalker
authors.forename: R F
authors.initials: RF
authors.lastname: Griffith
authors.forename: A A
authors.initials: AA
authors.lastname: Herbert
authors.forename: J G
authors.initials: JG
authors.lastname: Hickman
authors.forename: J M
authors.initials: JM
authors.lastname: Maloney
authors.forename: B H
authors.initials: BH
authors.lastname: Miller
authors.forename: E H
authors.initials: EH
authors.lastname: Tschen
authors.forename: R A
authors.initials: RA
authors.lastname: Chandraratna
authors.forename: J R
authors.initials: JR
authors.lastname: Gibson
authors.forename: D A
authors.initials: DA
authors.lastname: Lew-Kaya
authors.forename: J C
authors.initials: JC
authors.lastname: Lue
authors.forename: J
authors.initials: J
authors.lastname: Sefton
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005782:Gels / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D017060:Patient Satisfaction; D012176:Retinoids / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005782:Gels; D007641:Keratolytic Agents; D009539:Nicotinic Acids; D012176:Retinoids; C086827:tazarotene